This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...
The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...
ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...
